Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWITCH 2: Insulin Degludec vs Glargine in T2D
NCT02030600Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2014
- Primary completion
- Dec 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 3 trial of insulin degludec in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Jan 2014; status: completed.
02
Drugs
insulin degludec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02030600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02030600.